Mr. Richard Muruve reports

ARCH BIOPARTNERS ANNOUNCES ISSUANCE OF A SECOND U.S. PATENT FOR PEPTIDE SOLID SURFACE INTERFACE

The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 9,096,775 titled, "Surface-coated structures and methods" to Arch Biopartners Inc.

This patent further protects the company's peptide-solid surface technology which has been shown to reduce biofilm formation and corrosion on various solid surfaces and improve biocompatibility of certain plastics used in medical devices.

The issuance of this patent gives Arch commercial protection for this novel technology in the most lucrative pharmaceutical and industrial market in the world. Arch management anticipates that similar patents will be issued, in due course, in various major national markets that are members of the patent co-operation treaty.

The new U.S. patent issued today is the second related to Arch's peptide solid surface interface technology. On Feb. 25, 2015, Arch announced the USPTO issued patent No. 8,961,984 bearing the same name.

Arch management plans further commercial development of the technology in medical and industrial applications in the coming year.

"This patent issuance adds to the commercial prospects of the Arch portfolio. We continue to produce data showing that our unique peptides reduce corrosion of steel and inhibit biofilm formation on various steel and plastic surfaces. We have recently seen published data from our science team showing promise to improve the biocompatibility of polysulfone used in kidney dialysis. Having another patent issued by the USPTO on our technology is another important milestone toward our commercial goals," said Richard Muruve, chief executive officer of Arch.

The patent is based on a technology invented by Dr. Randall Irvin, Dr. Elisabeth Davis and Dr. D.Y. Li at the University of Alberta, and Dr. Daniel Muruve, chief science officer of Arch and professor at University of Calgary. The new patent has been assigned to Arch.

We seek Safe Harbor.